SAN DIEGO, February 15, 2022 – Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, today announced the appointment of Evert (Eef) Schimmelpennink to its Board of Directors. Mr. Schimmelpennink is a seasoned biotechnology executive with close to 25 years of experience spanning research and development, commercial growth, manufacturing, and business development.
“I am pleased to welcome Eef Schimmelpennink to Pipeline’s Board of Directors,” said Carmine Stengone, President and Chief Executive Officer of Pipeline Therapeutics. “Eef is a renowned leader in the life-sciences industry whose cross-functional leadership experience will be invaluable to Pipeline as we advance our neuroregeneration platform.”
“Pipeline has a very promising portfolio and a strong and thoughtful management team,” said Eef Schimmelpennink. “I welcome the opportunity to join the company on its journey to bring patients new options to address serious neurological disorders.”
Mr. Schimmelpennink currently serves as President and CEO of LENZ Therapeutics, a late-stage clinical company developing innovative ophthalmic pharmaceutical products that aim to improve vision. Prior to LENZ, Mr. Schimmelpennink was CEO and President of Pfenex, Inc. (NYSE: PFNX), up through its acquisition by Ligand Pharmaceuticals in 2020. Before his role at Pfenex, Mr. Schimmelpennink served as CEO for Alvotech, a private specialty biopharmaceutical company. From December 2012 to November 2015, Mr. Schimmelpennink held global marketing and strategy roles at Pfizer and Hospira.
Mr. Schimmelpennink currently serves on the Board of Directors for iBio, Inc. (NYSE:IBIO), where he is the chair of the Nominating and Corporate Governance Committee and a member of the Science and Technology Committee.
Mr. Schimmelpennink obtained his Master of Science in Bioprocess Engineering from Wageningen University & Research, as well as a degree from the Arnhem Business School.
About Pipeline Therapeutics
Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for precision neuroregeneration, including remyelination, synaptogenesis and axonal repair. Pipeline has two product candidates in clinical development: PIPE-307, targeting remyelination to treat multiple sclerosis, which recently completed a Phase 1 healthy volunteer study, and PIPE-505, targeting sensorineural hearing loss associated with speech-in-noise disability, which recently completed a Phase 1/2a study. In addition, Pipeline has a portfolio of further programs addressing a range of neurological disorders and conditions. For more information, please visit www.pipelinetherapeutics.com.
Company Contact:
Peter Slover
Chief Financial Officer
ir@pipeline-tx.com
Investor Contact:
Amy Conrad
858-914-1962
amy@juniper-point.com
